Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells

Use of epidermal growth factor receptor (EGFR) inhibitors represented by gefitinib and erlotinib has become the standard of treatment for non-small-cell lung cancers (NSCLCs) with activating EGFR mutations. However, the majority of NSCLCs, which overexpress EGFR without such mutations, are resistant...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Suzuki, Shuhei, Okada, Masashi, Takeda, Hiroyuki, Kuramoto, Kenta, Sanomachi, Tomomi, Togashi, Keita, Seino, Shizuka, Yamamoto, Masahiro, Yoshioka, Takashi, Kitanaka, Chifumi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135698/
https://ncbi.nlm.nih.gov/pubmed/30220973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25994
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi